Revvity (RVTY) Q2 2026 Earnings Call Transcript
Revvity (RVTY) reported Q2 2026 pro forma revenue of $711 million, up 3% organically, and pro forma adjusted EPS of $1.41. Diagnostics revenue rose 11% organically, while Signals software declined 20% organically. Free cash flow was $184 million. Full-year organic growth guidance was raised to 4% to 5% and adjusted EPS to $5.30 to $5.40.
How this was made
The 30-second read
Why it matters
The key tradable items are the raised full-year organic growth and adjusted EPS guidance, the Q3 growth and margin outlook, and the operational drivers cited (Diagnostics strength, Signals ARR/APV momentum, instrument backlog, and production capacity constraints).
Market read
Traders can reprice RVTY expectations based on the guidance raise, Q3 outlook, and the mix of improving Diagnostics/instruments versus temporary Signals software weakness.
What to watch
Instrument orders outpacing production capacity suggests revenue timing risk into later quarters, and the China immunodiagnostics divestment timeline to late 2027 may create ongoing transition costs and customer churn risk.
Background
Revvity reported Q2 2026 results via an earnings call transcript, highlighting segment organic growth, software performance, instrument backlog, and updated full-year and Q3 guidance.
Ticker impact
Revvity raised full-year organic growth guidance to 4% to 5% and adjusted EPS to $5.30 to $5.40 after Q2 results beat expectations.
Bias toward upside revisions and higher multiple support, with volatility around software re-acceleration and capacity constraints.
The article discloses multiple forward-looking datapoints (raised growth and EPS ranges, Q3 margin and growth guidance, backlog and ARR/APV momentum) that can drive estimates. Offsetting risks include a 20% organic Signals software decline and production capacity limiting instrument revenue capture, plus ongoing China-related restructuring.
Market effects
Signals AI and instrument demand tied to AI-driven drug discovery could support sentiment for life-science tools and informatics peers, but software growth deceleration highlights uneven demand within the segment.
Europe strength versus Americas software comparisons and latent TB pressures may shift regional allocation trades within diagnostics tools.
Tariff refund benefit and China immunodiagnostics divestment are company-specific, but they reinforce how trade policy and geographic mix can swing biotech-instrument earnings.
Counterpoint
The raised EPS range includes tariff refunds and the software segment still shows a 20% organic decline, so the earnings quality may be less durable than the headline guidance implies.
Key entities
- companyRevvity, Inc.
US-listed life-science tools and diagnostics company issuing Q2 results and raising full-year guidance.
- executivePrahlad Singh
CEO who discussed end-market demand, China challenges, and Lab-in-the-Loop/Signals AI direction.
- executiveMaxwell Krakowiak
CFO who discussed guidance, leverage, and geographic performance drivers like latent TB pressures.
